University of Pisa

Lunit's AI Platform Demonstrates Predictive Power for Immunotherapy Response Across Multiple Cancer Types at ESMO 2025

- Lunit's SCOPE IO artificial intelligence platform successfully predicted immunotherapy response in three major cancer types through analysis of routine histopathology slides presented at ESMO 2025. - In colorectal cancer trials, biomarker-high patients showed significantly improved progression-free survival and overall survival when treated with atezolizumab combinations compared to biomarker-low patients. - The AI tool demonstrated 60.5% response rates versus 23.2% for inflamed versus non-inflamed tumors in advanced clear cell renal cell carcinoma patients treated with nivolumab plus ipilimumab. - Validation studies across lung, kidney, and colorectal cancers support the platform's potential to guide personalized immunotherapy treatment selection in clinical practice.